Last reviewed · How we verify
MMR vaccine
The MMR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses by introducing live attenuated (weakened) forms of these pathogens.
The MMR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses by introducing live attenuated (weakened) forms of these pathogens. Used for Prevention of measles, Prevention of mumps, Prevention of rubella.
At a glance
| Generic name | MMR vaccine |
|---|---|
| Also known as | No other names, TRIMOVAX, Tresivac, M-M-RVAXPRO® |
| Sponsor | Sri Edupuganti, MD MPH |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains three live attenuated viral strains that replicate in vaccinated individuals without causing disease, triggering both humoral (antibody) and cell-mediated immune responses. This primes the immune system to recognize and rapidly neutralize wild-type measles, mumps, and rubella viruses upon natural exposure, preventing infection or reducing disease severity.
Approved indications
- Prevention of measles
- Prevention of mumps
- Prevention of rubella
Common side effects
- Fever
- Rash
- Injection site soreness or swelling
- Parotitis (mumps-like symptoms)
- Arthralgia or arthritis
Key clinical trials
- Live Vaccines and Innate Immune Training in COPD. (PHASE4)
- Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
- A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (PHASE3)
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (PHASE3)
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MMR vaccine CI brief — competitive landscape report
- MMR vaccine updates RSS · CI watch RSS
- Sri Edupuganti, MD MPH portfolio CI